Navigation Links
New type of sirolimus-eluting stent demonstrates superior results
Date:9/21/2009
loaded. The stent's design achieves both a significant reduction in total polymer load as well as a reduction in tissue-polymer contact by more than 75% compared to conventional DES in which the entire stent surface is coated with polymer. Its use of a bioresorbable polymer is another theoretical advantage from the safety perspective, allowing the drug-eluting stent to become simple bare metal within the vessel wall approximately 3 months after deployment.
In this clinical trial, detailed arterial responses to the new DES technology were also investigated in vivo using intravascular ultrasound (IVUS). With IVUS, a tiny catheter is inserted into a coronary vessel where high-frequency sound waves reflect off tissue or vessel walls. The reflected waves create a cross-sectional image from within the vessel to aid in visualizing its structure, thereby providing both quantitative and qualitative information on vessel reaction after stenting.
Serial IVUS (immediately post-stenting and 6-month follow-up) was performed in a pre-defined IVUS subset of 100 patients (52 SES in 50 patients; 52 PES in 50 patients). Volumetric IVUS analysis demonstrated significantly less neointimal proliferation in the sirolimus-eluting stent (% neointimal volume: 5.511.0 vs. 11.59.7, p=0.016), resulting in less late lumen area loss and smaller maximum cross-sectional narrowing (neointimal area/stent area) than PES. In addition, serial IVUS analysis revealed significantly less outward vessel remodeling in the SES than in PES. The incidence of late-acquired incomplete stent apposition (ISA) was similar between the SES and PES. However, SES was associated with less outward vessel remodeling at the ISA segment, possibly suggesting different underlying mechanisms of this phenomenon.
"Our study is the first report investigating the detailed arterial responses to this new DES technology, with a randomized, blinded comparison of sirolimus-eluting stents with paclitaxel-elut
'/>"/>
| Contact: Judy Romero jromero@crf.org 347-407-2774 Cardiovascular Research Foundation Source:Eurekalert |
Related medicine news :
1. Sono-Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer
2. Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed
3. Stent for life initiative
4. Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
5. Adding a Stent May Help Resolve Brain Aneurysm
6. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
7. Stenting a Good Option for Left Main Heart Artery
8. Stent Studies Tied to Rapid Changes in Use
9. QHR Client Hospitals Lauded for Consistently High Quality Standards, Exceeding Patient Expectations
10. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
11. AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
Post Your Comments:
(Date:5/17/2013)... found to have an abnormality on routine mammogram or ... up having an old-fashioned surgical biopsy to find out ... expert panels have recommended that the first course of ... be minimally invasive biopsy. , Minimally invasive biopsies are ... either a fine needle or preferably a "core tissue ...
(Date:5/17/2013)... when the U.S. health system is facing both an ... shortage of primary care physicians, one broadly recommended strategy ... of nurse practitioners. In 2010 an Institute of Medicine ... be able to practice to the full extent of ... be able to admit patients to hospitals and hospices, ...
(Date:5/17/2013)... Arrowhead, CA (PRWEB) May 17, 2013 ... extra health complications, but for diabetics, treatment is more ... involves additional medical care to monitor blood sugar levels ... addicted diabetic properly, a drug rehab for diabetics ... unique dietary and nutritional needs of the diabetic, and ...
(Date:5/17/2013)... "screen time" and sleep on mood, memory and ... at the 2013 Intel International Science and Engineering ... school students. The awards are coordinated by the ... the National Institutes of Health, and Friends of ... Intel ISEF Addiction Science Awards were presented at ...
(Date:5/17/2013)... May 17 (HealthDay News) -- Too few obstetrics-gynecology residents ... which could lead to care issues for the rapidly ... finds. Researchers surveyed 510 ob/gyn residents and found ... training in menopause medicine, even though seven in 10 ... 60 percent of fourth-year residents -- those soon to ...
Breaking Medicine News(10 mins):Health News:More than one-third of Texas women still receive unnecessary breast biopsy surgery 2Health News:Study finds disagreement on the role of primary care nurse practitioners 2Health News:Study finds disagreement on the role of primary care nurse practitioners 3Health News:Study finds disagreement on the role of primary care nurse practitioners 4Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 2Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 3Health News:Study of 'screen time' on mood, memory, and cognition wins top NIH Addiction Science Award 2Health News:Study of 'screen time' on mood, memory, and cognition wins top NIH Addiction Science Award 3Health News:Study of 'screen time' on mood, memory, and cognition wins top NIH Addiction Science Award 4Health News:Is Menopause Overlooked in U.S. Medical Schools? 2[0] More than one-third of Texas women still receive unnecessary breast biopsy surgery[0] Study finds disagreement on the role of primary care nurse practitioners[0] Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics[0] Study of 'screen time' on mood, memory, and cognition wins top NIH Addiction Science Award[0] Is Menopause Overlooked in U.S. Medical Schools?
... and nearly 500 others who ate at a Chi-Chi's Mexican ... hepatitis A in U.S.// history, making people so scared they ... longer eating out. ,Health investigators are focusing on ... at the restaurant in the Beaver Valley Mall, about 25 ...
... taking nonsteroidal anti-inflammatory drugs (NSAIDs) before and after knee ... ,Researchers from Rush University Medical Center in Chicago studied ... of the patients were randomly assigned to receive 50 ... two hours before the surgery, 50 milligrams each day ...
... surprising finding worried doctors, who say women will now have ... taking a daily aspirin.// ,Pancreatic cancer affects only 31,000 ... within three years. ,The study of 88,000 nurses found ... for 20 years or more had a 58 percent higher ...
... infusing heart attack patients with high density lipoprotein may ... the Cleveland Clinic injected patients with a laboratory-produced version ... buildups from arteries. Thirty-six patients received doses of HDL, ... received doses of saline. ,Researchers say they got ...
... virus that killed 774 people remains unknown. Scientists believe people may ... source.// ,"You might want to quarantine the pets as ... emerging diseases at the University of Texas Medical Branch in Galveston. ... to cat, it doesn't take much of a leap of faith ...
... as a disease of the past. New research shows ... should start before birth and researchers suggest pregnant women ... a childhood disorder involving softening and weakening of the ... or phosphate. It is most likely to occur during ...
Cached Medicine News:Health News:Aspirin usage linked with pancreatic cancer 2Health News:Some pets found to be SARS carriers 2(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)... and SYDNEY , May 16, ... - ASX: HIN), a leading innovator of less invasive, miniaturized ... heart failure, today announced that CEO Doug Godshall ... Global Healthcare Conference at 11:00 a.m. EDT on Monday, May ... at the Sheraton New York Hotel. A live ...
(Date:5/16/2013)... 16, 2013 ULURU Inc. (OTCQB: ULUR) today announced its ... and provided a review of its operating activities. ... the previously communicated outlook for 2013: , Launching Altrazeal ... network of distribution partners to cover all major markets excluding ... ® to be marketed in approximately 50 markets by ...
Breaking Medicine Technology:A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2ULURU Inc. Reports First Quarter 2013 Financial Results 2ULURU Inc. Reports First Quarter 2013 Financial Results 3ULURU Inc. Reports First Quarter 2013 Financial Results 4ULURU Inc. Reports First Quarter 2013 Financial Results 5... A new study from The Lewin Group ... $30 billion over the next decade by transitioning from ... programs to the more efficient approaches used by Medicare ... the commercial sector, including typical state employee plans. ...
... 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. has ... first-in-class CK2 inhibitor at the 52nd Annual Meeting of the ... 4-7 in Orlando, FL, the company announced today. Kenna Anderes, ... CK2, a protein kinase that is essential for the progression ...
Cached Medicine Technology:States, Federal Government Could Save $30 Billion by Managing Medicaid Pharmacy More Like Medicare and Commercial Sector Programs 2States, Federal Government Could Save $30 Billion by Managing Medicaid Pharmacy More Like Medicare and Commercial Sector Programs 3Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 2Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 3| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |